Medicare Finalizes 340B Drug Pay At Average Sales Price Minus 28% For 2027
The final 2027 outpatient rule cuts drug payments by $4.35 billion in year one and shifts the money to non-drug services.
The Centers for Medicare & Medicaid Services (CMS) finalized a 2027 outpatient payment rule on Wednesday that pays 340B-acquired drugs at average sales price minus 28%, which the agency estimates will cut Original Medicare drug payment by $4.35 billion in the first year. Because statute requires budget neutrality, CMS said, payments for non-drug services will rise by an equivalent amount.
The 340B cut and who pays
CMS said it estimates beneficiary drug payments will fall by $1.1 billion in the first year, and that a patient receiving a qualifying drug in a hospital outpatient department is expected to save an average of $900 in drug costs in 2027.
The agency based the change on a survey of hospital drug acquisition costs run from Jan. 1, 2026, through April 7, 2026. CMS said the survey found significant disparities between drugs bought through the 340B program and those bought outside it, and in some cases found that the beneficiary cost-sharing amount, typically 20% of the total payment, exceeded the hospital's price for the drug.
The survey follows an April 2025 executive order from President Trump that directed HHS to publish a plan for it.
A bigger offset on non-drug pay
CMS also raised the annual offset on non-drug items and services from 0.5% to 2%, excluding hospitals that enrolled in Medicare after Jan. 1, 2018. The offset recoups increased non-drug payments made from 2018 through 2022 under the earlier 340B policy, and it runs until it reaches $7.8 billion, which CMS estimates will happen in 2031.
CMS proposed a 2% reduction for 2026 but did not finalize it. It said then that it expected an increase beyond 0.5% in 2027.
Rates, imaging and the inpatient list
Hospital outpatient and ambulatory surgical center rates rise 2.3% for 2027, from a projected 3.2% market basket increase less a 0.9 percentage point productivity adjustment. The rule touches about 3,500 hospitals and about 6,400 ambulatory surgical centers.
CMS will extend its site-neutral payment method to imaging without contrast, including certain bone density scans, x-rays, ultrasounds, CT scans and MRIs at excepted off-campus hospital departments. It will pay the physician-office-equivalent rate, and rural Sole Community Hospitals are exempt. CMS estimates the change cuts Medicare Part B expenditures by about $260 million in the first year: about $190 million in Part B savings and about $70 million in lower beneficiary premiums.
In the second year of a three-year phase-out, CMS removes 637 services from the inpatient-only list. It also adds a cost-of-living adjustment for Alaska and Hawaii, projected to raise payments to hospitals there by $66 million in 2027.
CMS estimates the 2% offset on non-drug services will keep running until 2031.
Sources
- Calendar Year 2027 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Final Rule (CMS-1850-F) — Centers for Medicare & Medicaid Services
- The 2026 election wins could allow Democrats to tackle healthcare costs. What can they do? | Vox — vox.com
- Medicare spends more on hospices owned by private equity firms, study finds | Healthcare Dive — healthcaredive.com
- Democrats' election rout is poised to dramatically reorder federal health policy - CBS News — CBS News
- Medicare's CJR-X Mandate Shifts $392M From Hospitals. ROMTech®'s AI Helps Them Win It Back. — Yahoo Finance
- Medicare's CJR-X Mandate Shifts $392M From Hospitals. ROMTech®'s AI Helps Them Win It Back. — prnewswire.com